Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Shenzhen - Delayed Quote CNY

Tiansheng Pharmaceutical Group Co., Ltd. (002872.SZ)

Compare
3.8500
+0.0300
+(0.79%)
At close: April 11 at 3:04:06 PM GMT+8
Loading Chart for 002872.SZ
  • Previous Close 3.8200
  • Open 3.8400
  • Bid 3.8500 x --
  • Ask 3.8600 x --
  • Day's Range 3.7800 - 3.9000
  • 52 Week Range 3.1700 - 5.1400
  • Volume 1,435,050
  • Avg. Volume 3,225,681
  • Market Cap (intraday) 1.224B
  • Beta (5Y Monthly) 0.13
  • PE Ratio (TTM) --
  • EPS (TTM) -0.1500
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date Aug 22, 2018
  • 1y Target Est --

Tiansheng Pharmaceutical Group Co., Ltd. engages in the pharmaceutical manufacturing and circulation activities. It offers products in various categories, including respiratory, digestive, cardiovascular and cerebrovascular, pediatric, gynecological, orthopedic, oncology, hepatobiliary, blood, surgery, diabetes, and others. The company was founded in 2001 and is based in Chongqing, China.

www.tszy.com.cn

1,289

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 002872.SZ

View More

Performance Overview: 002872.SZ

Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

002872.SZ
15.20%
SSE Composite Index (000001.SS)
3.39%

1-Year Return

002872.SZ
20.29%
SSE Composite Index (000001.SS)
6.72%

3-Year Return

002872.SZ
29.62%
SSE Composite Index (000001.SS)
2.24%

5-Year Return

002872.SZ
32.69%
SSE Composite Index (000001.SS)
15.79%

Compare To: 002872.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 002872.SZ

View More

Valuation Measures

Annual
As of 4/11/2025
  • Market Cap

    1.22B

  • Enterprise Value

    1.34B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.13

  • Price/Book (mrq)

    0.60

  • Enterprise Value/Revenue

    2.32

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -8.27%

  • Return on Assets (ttm)

    -1.18%

  • Return on Equity (ttm)

    -2.33%

  • Revenue (ttm)

    575.3M

  • Net Income Avi to Common (ttm)

    -47.6M

  • Diluted EPS (ttm)

    -0.1500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    243.03M

  • Total Debt/Equity (mrq)

    19.24%

  • Levered Free Cash Flow (ttm)

    -22.03M

Research Analysis: 002872.SZ

View More

Company Insights: 002872.SZ

Research Reports: 002872.SZ

View More

People Also Watch